Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
D'Amore, F Radford, John A Relander, T Jerkeman, M Tilly, H Osterborg, A Morschhauser, F Gramatzki, M Dreyling, M Bang, B
D'Amore, F
Radford, John A
Relander, T
Jerkeman, M
Tilly, H
Osterborg, A
Morschhauser, F
Gramatzki, M
Dreyling, M
Bang, B
Citations
Altmetric:
Abstract
The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.
Description
Date
2010-09
Publisher
Collections
Keywords
Lymphoma
CD4
Angioimmunoblast
Anaplastic
Zanolimumal
CD4
Angioimmunoblast
Anaplastic
Zanolimumal
Type
Article
Citation
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. 2010, 150 (5):565-73 Br J Haematol